Generic name: hydrocodone bitartrate, pseudoephedrine hydrochloride and guaifenesin
Dosage form: oral solution
Drug class: Upper respiratory combinations
Medically reviewed by Drugs.com. Last updated on Jul 22, 2020.
On This Page
- Indications and Usage
- Dosage and Administration
- Dosage Forms and Strengths
- Warnings and Precautions
- Adverse Reactions/Side Effects
- Drug Interactions
- Use In Specific Populations
- Drug Abuse and Dependence
- Clinical Pharmacology
- Nonclinical Toxicology
- Clinical Studies
- How Supplied/Storage and Handling
Indications and Usage for Hycofenix
Hycofenix is indicated for symptomatic relief of cough, nasal congestion, and to loosen mucus associated with the common cold.
Important Limitations of Use:
Not indicated for pediatric patients under 18 years of age [ see Pediatric Use (8.4)].
Hycofenix Dosage and Administration
2.1 Recommended Dosage
Adults and adolescents 18 years of age and older: 10 mL every 4 to 6 hours, not to exceed 4 doses (40 mL) in 24 hours.
Administer Hycofenix by the oral route only. Measure Hycofenix with an accurate milliliter measuring device. Do not use a household teaspoon to measure the dose [ see Warnings and Precautions (5.10)].
Dosage Forms and Strengths
Oral solution: Each 5 mL contains hydrocodone bitartrate, USP, 2.5 mg; pseudoephedrine hydrochloride, USP, 30 mg; and guaifenesin, USP, 200 mg [ see Description (11)].
Hycofenix is contraindicated in:
• Patients with known hypersensitivity to hydrocodone bitartrate, pseudoephedrine hydrochloride, guaifenesin, or any of the inactive ingredients of Hycofenix.
• Patients receiving MAOI therapy or within 14 days of stopping such therapy [ see Drug Interactions (7.2)].
• Patients with narrow angle glaucoma, urinary retention, severe hypertension, or severe coronary artery disease.
Warnings and Precautions
5.1 Respiratory Depression
Hydrocodone bitartrate, one of the active ingredients in Hycofenix, produces doserelated respiratory depression by directly acting on brain stem respiratory centers. Overdose of hydrocodone bitartrate in adults has been associated with fatal respiratory depression, and the use of hydrocodone bitartrate in children less than 6 years of age has been associated with fatal respiratory depression. Exercise caution when administering Hycofenix because of the potential for respiratory depression. If respiratory depression occurs, it may be antagonized by the use of naloxone hydrochloride and other supportive measures when indicated [ see Overdosage (10)].
5.2 Drug Dependence
Hydrocodone can produce drug dependence of the morphine type and therefore, has the potential for being abused. Psychic dependence, physical dependence, and tolerance
may develop upon repeated administration of Hycofenix. Prescribe and administer Hycofenix with the same degree of caution appropriate to the use of other opioid drugs [ see Drug Abuse and Dependence (9.2), (9.3)].
5.3 Head Injury and Increased Intracranial Pressure
The respiratory depression effects of opioids and their capacity to elevate cerebrospinal fluid pressure may be markedly exaggerated in the presence of head injury, other intracranial lesions, or a pre-existing increase in intracranial pressure. Furthermore, opioids produce adverse reactions which may obscure the clinical course of patients with head injuries. The use of Hycofenix should be avoided in these patients.
5.4 Activities Requiring Mental Alertness
Hydrocodone bitartrate, one of the active ingredients in Hycofenix, may produce marked drowsiness and impair the mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery. Advise patients to avoid engaging in hazardous tasks requiring mental alertness and motor coordination after ingestion of Hycofenix. Concurrent use of Hycofenix with alcohol or other central nervous system depressants should be avoided because additional impairment of central nervous system performance may occur.
5.5 Acute Abdominal Conditions
Hycofenix should be used with caution in patients with acute abdominal conditions since the administration of hydrocodone may obscure the diagnosis or clinical course of
patients with acute abdominal conditions. The concurrent use of other anticholinergics with hydrocodone may produce paralytic ileus [ see Drug Interactions (7.3)].
5.6 Co-administration with Anticholinergics
The concurrent use of anticholinergics with hydrocodone may produce paralytic ileus. Exercise caution when using Hycofenix in patients taking anticholinergic medications
[ see Drug Interactions (7.3)].
5.7 Co-administration with Monoamine Oxidase Inhibitors (MAOIs) or Tricyclic Antidepressants
Hycofenix should not be used in patients receiving MAOI therapy or within 14 days of stopping such therapy. The use of MAOIs or tricyclic antidepressants with hydrocodone bitartrate may increase the effect of either the antidepressant or hydrocodone [ see Contraindications (4) and Drug Interactions (7.2)].
5.8 Cardiovascular and Central Nervous System Effects
The pseudoephedrine hydrochloride contained in Hycofenix can produce cardiovascular and central nervous system effects in some patients such as insomnia, dizziness, weakness, tremor, or arrhythmias. In addition, central nervous system stimulation with convulsions or cardiovascular collapse with accompanying hypotension has been reported. Therefore, Hycofenix should be used with caution in patients with cardiovascular disorders, and should not be used in patients with severe hypertension or coronary artery disease.
5.9 Persistent Cough
Hycofenix should not be used in patients with a persistent or chronic cough such as occurs with smoking, asthma, chronic bronchitis, or emphysema, or where cough
is accompanied by excessive phlegm (mucus).
Patients should be advised to measure Hycofenix with an accurate milliliter measuring device. Patients should be informed that a household teaspoon is not an accurate
measuring device and could lead to overdosage, which can result in serious adverse reactions [ see Overdosage (10)]. Patients should be advised to ask their pharmacist to
recommend an appropriate measuring device and for instructions for measuring the correct dose.
5.11 Coexisting Conditions
Hycofenix should be used with caution in patients with diabetes, thyroid disease, Addison’s disease, prostatic hypertrophy or urethral stricture, and asthma.
5.12 Renal Impairment
Hycofenix should be used with caution in patients with severe renal impairment [ see Use in Specific Populations (8.6)].
5.13 Hepatic Impairment
Hycofenix should be used with caution in patients with severe hepatic impairment [ see Use in Specific Populations (8.7)].
Use of hydrocodone bitartrate is associated with the following:
• Respiratory depression [ see Warnings and Precautions (5.1) and Overdosage (10)]
• Drug dependence [ see Warnings and Precautions (5.2) and Drug Abuse and Dependence (9.3)]
• Increased intracranial pressure [ see Warnings and Precautions (5.3)]
• Decreased mental alertness with impaired mental and/or physical abilities [ see Warnings and Precautions (5.4)]
• Paralytic ileus [ see Warnings and Precautions (5.5)]
Use of pseudoephedrine, a sympathomimetic amine, may result in the following:
• Central nervous system effects such as insomnia, dizziness, weakness, tremor, or convulsions [ see Warnings and Precautions (5.8)]
• Cardiovascular system effects such as arrhythmias, or increased blood pressure, cardiovascular collapse with accompanying hypotension [ see Warnings and Precautions 5.8)]
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
The most common adverse reactions experienced by subjects taking a single dose of Hycofenix in the clinical setting include the following: Central Nervous System: headache, dizziness, sedation (somnolence); Gastrointestinal System: nausea, diarrhea; Cardiovascular System: decreased blood pressure; Vascular System: hot flush.
No specific interaction studies have been conducted with Hycofenix.
7.1 Opioids, Antihistamines, Antipsychotics, Anti-anxiety Agents, or Other CNS Depressants (Including Alcohol)
The use of opioids, antihistamines, antipsychotics, anti-anxiety agents, or other CNS depressants concomitantly with Hycofenix may cause an additive CNS depressant effect and should be avoided.
7.2 MAO Inhibitors or Tricyclic Antidepressants
Do not prescribe Hycofenix if the patient is taking a prescription MAOI (i.e., certain drugs used for depression, psychiatric or emotional conditions, or Parkinson’s
disease), or for 2 weeks after stopping a MAOI drug. The use of MAOIs or tricyclic antidepressants with hydrocodone preparations may increase the effect of either the
antidepressant or hydrocodone. An increase in blood pressure of hypertensive crisis may also occur when pseudoephedrine containing preparations are used with MAOIs
[ see Warnings and Precautions (5.7)].
7.3 Anticholinergic Drugs
Hydrocodone should be administered cautiously to persons receiving anticholinergic drugs in order to avoid paralytic ileus and excessive anticholinergic effects [ see
Warnings and Precautions (5.6) ].
USE IN SPECIFIC POPULATIONS
Pregnancy Category C
There are no adequate and well controlled studies of Hycofenix in pregnant women. Reproductive toxicity studies have not been conducted with Hycofenix; however, studies are available with an individual active ingredient or related active ingredient. Hydrocodone was teratogenic in hamsters. Codeine, an opiate related to hydrocodone, increased resorptions and decreased fetal weight in rats. Because animal reproduction studies are not always predictive of human response, Hycofenix should be used during pregnancy only if the benefit justifies the potential risk to the fetus.
Hydrocodone has been shown to be teratogenic in hamsters when given in a dose approximately 35 times the maximum recommended human daily dose (MRHDD) (on a mg/m 2 basis at a single subcutaneous dose of 102 mg/kg on gestation day 8). Reproductive toxicology studies were also conducted with codeine, an opiate related to hydrocodone. In a study in which pregnant rats were dosed throughout organogenesis, a dose of codeine approximately 50 times the MRHDD of hydrocodone (on a mg/m 2 basis at an oral dose of 120 mg/kg/day of codeine) increased resorptions and decreased fetal weight; however, these effects occurred in the presence of maternal toxicity. In studies in which rabbits and mice were dosed throughout organogenesis, doses of codeine up to approximately 25 and 120 times, respectively, the MRHDD of hydrocodone (on a mg/m 2 basis at oral doses of 30 and 600 mg/kg/day, respectively), produced no adverse developmental effects.
Babies born to mothers who have been taking opioids regularly prior to delivery will be physically dependent. The withdrawal signs include irritability and excessive crying, tremors, hyperactive reflexes, increased respiratory rate, increased stools, sneezing, yawning, vomiting, and fever. The intensity of the syndrome does not always correlate with the duration of maternal opioid use or dose.
8.2 Labor and Delivery
As with all opioids, administration of Hycofenix to the mother shortly before delivery may result in some degree of respiratory depression in the newborn, especially if higher doses are used.
8.3 Nursing Mothers
Caution should be exercised when Hycofenix is administered to nursing mothers. Hydrocodone and pseudoephedrine are known to be excreted in human milk. No studies have been performed to determine if guaifenesin is excreted into breastmilk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from Hycofenix, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
8.4 Pediatric Use
Safety and effectiveness of Hycofenix in pediatric patients under 18 years of age has not been established. The use of hydrocodone in children less than 6 years of age is associated with fatal respiratory depression [ see Warnings and Precautions (5.1)].
8.5 Geriatric Use
Clinical studies have not been conducted with Hycofenix in geriatric populations. Other reported clinical experience with the individual active ingredients of Hycofenix has not identified differences in responses between the elderly and patients younger than 65 years of age. In general, dose selection for an elderly patient should be made with caution, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. The pseudoephedrine contained in Hycofenix is known to be substantially excreted by the kidney and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.
8.6 Renal Impairment
Hycofenix should be given with caution in patients with severe impairment of renal function. Pseudoephedrine is primarily excreted unchanged in the urine as unchanged drug with the remainder apparently being metabolized in the liver. Therefore, pseudoephedrine may accumulate in patients with renal impairment.
8.7 Hepatic Impairment
Hycofenix should be given with caution in patients with severe impairment of hepatic function.
Drug Abuse and Dependence
9.1 Controlled Substance
Hycofenix is a Schedule II controlled prescription containing hydrocodone bitartrate and should be prescribed and administered with caution.
Hydrocodone can produce drug dependence of the morphine type and therefore, has the potential for being abused. Psychic dependence, physical dependence, and tolerance may develop upon repeated administration of Hycofenix, and it should be prescribed and administered with the same degree of caution appropriate to the use of other opioid drugs.
Abuse of guaifenesin has been linked to the formation of kidney stones composed of the major metabolite β-(2-methoxyphenoxy) lactic acid.
Psychic dependence, physical dependence, and tolerance may develop upon repeated administration of opioids; therefore, Hycofenix should be prescribed and administered with caution [ see Warnings and Precautions (5.2)].
Physical dependence, the condition in which continued administration of the drug is required to prevent the appearance of a withdrawal syndrome, assumes clinically significant proportions only after several weeks of continued oral opioid use, although some mild degree of physical dependence may develop after a few days of opioid therapy.
No human overdosage data are available for Hycofenix.
Overdosage with hydrocodone is characterized by respiratory depression (a decrease in respiratory rate and/or tidal volume, Cheyne-Stokes respiration, cyanosis), extreme somnolence progressing to stupor or coma, skeletal muscle flaccidity, dizziness, ringing in the ears, confusion, blurred vision, eye problems, cold and clammy skin, and sometimes bradycardia and hypotension. In severe overdose, apnea, circulatory collapse, cardiac arrest and death may occur.
Overdosage with sympathomimetics such as pseudoephedrine may give rise to giddiness, headache, nausea, vomiting, sweating, thirst, tachycardia, precordial pain, palpitations, difficulty in micturition, muscle weakness and tenseness, anxiety, restlessness, and insomnia. Many patients can present a toxic psychosis with delusion and hallucinations. Some may develop cardiac arrhythmias, circulatory collapse, convulsion, coma, and respiratory failure.
Overdosage with guaifenesin can cause depression of the central nervous system. While present in polypharmacy overdoses, one case of overdose with only significant levels of guaifenesin has been reported. Symptoms included slurred speech, shallow respirations, reduced heart rate with rhythm sinus bradycardia, followed by asystole.
Treatment of overdosage consists of discontinuation of Hycofenix together with institution of appropriate therapy. Primary attention should be given to the reestablishment of adequate respiratory exchange through provision of a patent airway and the institution of assisted or controlled ventilation. The opioid antagonist naloxone hydrochloride is a specific antidote for respiratory depression which may result from overdosage or unusual sensitivity to opioids including hydrocodone. Therefore, an appropriate dose of naloxone hydrochloride should be administered, preferably by the intravenous route, simultaneously with efforts at respiratory resuscitation. For further information, see full prescribing information for naloxone hydrochloride. An antagonist should not be administered in the absence of clinically significant respiratory depression. Oxygen, intravenous fluids, vasopressors, and other supportive measures should be employed as indicated. Gastric emptying may be useful in removing unabsorbed drug.
Hycofenix (hydrocodone bitartrate, pseudoephedrine hydrochloride, and guaifenesin) oral solution contains hydrocodone bitartrate (a centrally-acting opioid antitussive), pseudoephedrine hydrochloride (an indirect sympathomimetic amine), and guaifenesin (an expectorant).
Each 5 mL dose of Hycofenix contains: hydrocodone bitartrate, USP, 2.5 mg; pseudoephedrine hydrochloride, USP, 30 mg; and guaifenesin, USP, 200 mg.
Hycofenix also contains: black raspberry flavor, citric acid, D&C Red #33, FD&C Blue #1, glycerin, methylparaben, polyethylene glycol, propylparaben, purified water, saccharin sodium, sodium citrate, and sorbitol.
Hydrocodone bitartrate is a centrally-acting opioid antitussive and analgesic. It is affected by light and occurs as fine white crystals or crystalline powder which is derived from the opium alkaloid, thebaine. Its chemical name is morphinan-6-one, 4,5-epoxy-3-methoxy- 17-methyl-, (5α)-, [R-(R*,R*)]-2,3-dihydroxybutanedioate (1:1), hydrate (2:5). It is also known as 4,5α-Epoxy-3-methoxy-17-methylmorphinan-6-one tartrate (1:1) hydrate (2:5);and may be represented by the following structural formula:
Pseudoephedrine hydrochloride is benzenemethanol, α-[1-(methylamino)ethyl]-, [S-(R*,R*)] hydrochloride and has the following chemical structure:
Guaifenesin is an expectorant and occurs as a white powder. Its chemical name is 3-(2-methoxyphenoxy)-1,2-propanediol, and may be represented by the following structural formula:
Hycofenix - Clinical Pharmacology
12.1 Mechanism of Action
Hydrocodone is a semisynthetic narcotic antitussive and analgesic with multiple actions qualitatively similar to those of codeine. The precise mechanism of action of hydrocodone and other opiates is not known; however, hydrocodone is believed to act directly on the cough center. In excessive doses, hydrocodone will depress respiration. Hydrocodone can produce miosis, euphoria, and physical and physiological dependence.
Pseudoephedrine hydrochloride is an orally active sympathomimetic amine and exerts a decongestant action on the nasal mucosa. Pseudoephedrine hydrochloride is recognized as an effective agent for the relief of nasal congestion due to upper respiratory allergies or common cold. Pseudoephedrine produces peripheral effects similar to those of ephedrine and central effects similar to, but less intense than, amphetamines. It has the potential for excitatory side effects.
Guaifenesin is an expectorant the action of which promotes or facilitates the removal of secretions from the respiratory tract. The precise mechanism of action of guaifenesin is not known; however, it is thought to act as an expectorant by increasing the volume and reducing the viscosity of secretions in the trachea and bronchi. In turn, this may increase the efficiency of the cough reflex and facilitate removal of the secretions.
Systemic exposure (in terms of peak plasma concentrations and area under plasma concentration versus time curve) of hydrocodone bitartrate, pseudoephedrine hydrochloride, and guaifenesin after a single 10 mL oral dose administration of 5 mg hydrocodone bitartrate, 60 mg pseudoephedrine hydrochloride, and 400 mg guaifenesin are equivalent to the respective reference solutions of 5 mL hydrocodone bitartrate (5 mg/5 mL), 5 mL pseudoephedrine hydrochloride (30 mg/5 mL), and 10 mL guaifenesin (200 mg/5 mL).
Following a single 10 mL oral dose administration of 5 mg hydrocodone bitartrate, 60 mg pseudoephedrine hydrochloride, and 400 mg guaifenesin administered to 37 healthy adults, the geometric mean C max and AUC 0-inf for hydrocodone were 9.0 ng/mL and 61.2 ng·hr/mL, respectively. The median time to maximum concentration for hydrocodone was about 1.67 hours. Food has no significant effect on the extent of absorption of hydrocodone. The mean plasma half-life of hydrocodone is approximately 4 hours.
Following a single 10 mL oral dose administration of 5 mg hydrocodone bitartrate, 60 mg pseudoephedrine hydrochloride, and 400 mg guaifenesin administered to 37 healthy adults, the geometric mean C max and AUC 0-inf for pseudoephedrine were 0.19 mcg/mL and 1.9 mcg·hr/mL, respectively. The median time to maximum concentration for pseudoephedrine was about 2.5 hours. Food has no significant effect on the extent of absorption of pseudoephedrine. The mean plasma half-life of pseudoephedrine is approximately 6 hours.
Following a single 10 mL oral dose administration of 5 mg hydrocodone bitartrate, 60 mg pseudoephedrine hydrochloride, and 400 mg guaifenesin administered to 36 healthy adults, the geometric mean C max and AUC 0-inf for guaifenesin were 2.0 mcg/mL and 2.6 mcg·hr/mL, respectively. The median time to maximum concentration was about 25 minutes. The effect of food on guaifenesin systemic exposure is not considered to be clinically meaningful. The mean plasma half-life of guaifenesin is approximately 1 hour.
When guaifenesin, pseudoephedrine, and hydrocodone were administered in combination, the pharmacokinetics for each component was similar to those observed when each component was administered separately.
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
Carcinogenicity, mutagenicity, and reproductive studies have not been conducted with Hycofenix; however, published information is available for the individual active ingredients or related active ingredients.
Carcinogenicity studies were conducted with codeine, an opiate related to hydrocodone. In 2 year studies in F344/N rats and B6C3F1 mice, codeine showed no evidence of tumorigenicity at dietary doses up to 70 and 400 mg/kg/day, respectively (approximately 30 and 80 times, respectively, the MRHDD of hydrocodone on a mg/m2 basis).
Two-year feeding studies in rats and mice demonstrated no evidence of carcinogenic potential with ephedrine sulfate, a structurally related drug with pharmacological properties similar to pseudoephedrine, at dietary doses up to 10 and 27 mg/kg, respectively (approximately 0.3 and 0.5 times, respectively, the MRHDD of pseudoephedrine hydrochloride on a mg/m 2 basis).
Carcinogenicity, genotoxicity, or reproductive toxicology studies have not been conducted with guaifenesin.
Efficacy studies were not conducted with Hycofenix. Efficacy of Hycofenix is based on demonstration of bioequivalence to the individual comparator products [ see Clinical Pharmacology (12.3)].
How Supplied/Storage and Handling
Hycofenix (hydrocodone bitartrate, pseudoephedrine hydrochloride, and guaifenesin) oral solution is supplied as a violet-colored, black raspberry flavored liquid containing 2.5 mg hydrocodone bitartrate, 30 mg pseudoephedrine hydrochloride, and 200 mg guaifenesin in each 5 mL. It is available in:
White HDPE bottles of 16 fl. oz. (473 mL): NDC 0178-3291-16
White HDPE bottles of 4 fl. oz. (118 mL): NDC 0178-3291-04
Store solution at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]
Dispense in a tight, light-resistant container, as defined in the USP, with a childresistant closure.
Patient Counseling Information
Advise patients not to increase the dose or dosing frequency of Hycofenix because serious adverse events such as respiratory depression may occur with overdosage [ see Warnings and Precautions (5.1) and Overdosage (10)].
Advise patients to measure Hycofenix with an accurate milliliter measuring device. Patients should be informed that a household teaspoon is not an accurate measuring device and could lead to overdosage, especially when half a teaspoon is measured. Patients should be advised to ask their pharmacist to recommend an appropriate measuring device and for instructions for measuring the correct dose [ see Dosage and Administration (2) and Warnings and Precautions (5.10)].
Concomitant Use of Alcohol and Other Central Nervous System Depressants
Advise patients to avoid the use of alcohol and other central nervous system depressants while taking Hycofenix because additional reduction in mental alertness may occur [ see Warnings and Precautions (5.4)].
Activities Requiring Mental Alertness
Advise patients to avoid engaging in hazardous tasks that require mental alertness and motor coordination such as operating machinery or driving a motor vehicle as Hycofenix may produce marked drowsiness [ see Warnings and Precautions (5.4)].
Caution patients that Hycofenix contains hydrocodone bitartrate and can produce drug dependence [ see Warnings and Precautions (5.2)].
Patients should be informed that due to its pseudoephedrine component, they should not use Hycofenix with an MAOI or within 14 days of stopping use of an MAOI [ see Warning and Precautions (5.7)].
MISSION PHARMACAL COMPANY
San Antonio, TX 78230 1355
hydrocodone bitartrate, pseudoephedrine hydrochloride, guaifenesin liquid
|Labeler - Mission Pharmacal Company (008117095)|
More about Hycofenix (guaifenesin / hydrocodone / pseudoephedrine)
- Side Effects
- During Pregnancy
- Dosage Information
- Drug Interactions
- En Español
- Drug class: upper respiratory combinations